Alzheimer’s Disease (Central Nervous System) – Drugs In Development, 2021
- Pages: 2055
- Published: June 2021
- Report Code: GMDHC12859IDB
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease (Central Nervous System) – Drugs In Development, 2021, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.
Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease (Central Nervous System) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 23, 62, 86, 1, 4, 358, 178 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 3, 107 and 52 molecules, respectively.
Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies mentioned
1st Bio Therapeutics Inc
2A Pharma AB
4B Technologies (Suzhou) Co Ltd
4P-Pharma SAS
AB Science SA
Abaxy Sprl
AbbVie Inc
Abrexa Pharmaceuticals Inc
AC Immune SA
Acadia Pharmaceuticals Inc
Accuitis Pharmaceuticals Inc
Acelot Inc
Actinogen Medical Ltd
Acumen Pharmaceuticals Inc
Addex Therapeutics Ltd
ADEL Inc
Adocia SAS
ADRx Inc
Aerobyx LLC
Avidin Biotechnology Ltd
Avineuro Pharmaceuticals Inc
Axon Neuroscience SE
Axxam SpA
AZTherapies Inc
Berg LLC
BeyondBio Inc
Bio-Pharm Solutions Co Ltd
BioArctic AB
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Biom Therapeutics LLC
Biorchestra Ltd
BioSplice Therapeutics Inc
BioVie Inc
BioXcel Therapeutics Inc
Bisichem Co Ltd
Boehringer Ingelheim International GmbH
Bolden Therapeutics Inc
Bolder Biotechnology Inc
Boryung Pharmaceutical Co Ltd
Brain Innovation Co Ltd
BrainStorm Cell Therapeutics Inc
Brainvectis SAS
Corium Inc
Cortexyme Inc
Cortice Biosciences Inc
Covalent Bioscience Inc
Coya Therapeutics Inc
Creative Bio-Peptides Inc
Crossbeta Biosciences BV
CuroNZ Ltd
Cyclerion Therapeutics Inc
Cyclo Therapeutics Inc
CycloLab Cyclodextrin Research and Development Laboratory Ltd
Dadang & BIO Co Ltd
Daewoong Pharmaceutical Co Ltd
Immunwork Inc
Inmune Bio Inc
InnoBioscience LLC
InnoPharmaScreen Inc
Kwang Dong Pharmaceutical Co Ltd
Kyowa Kirin Co Ltd
Lacerta Therapeutics Inc
Landos Biopharma Inc
Lauren Sciences LLC
Lead Discovery Center GmbH
LEXEO Therapeutics LLC
Libella Gene Therapeutics
Light Chain Bioscience
Longeveron Inc
LSL Neurosciences LLC
Lyndra Therapeutics Inc.
MetrioPharm AG
MetVital Inc
MGC Pharmaceuticals Ltd
Mindset Pharma Inc
Mission Therapeutics Ltd
Mitoconix Bio Ltd
Modag GmbH
Montisera Ltd
NAL Pharmaceuticals Ltd
Nanomerics Ltd
NatureWise Biotech & Medicals Corp
Neonc Technologies Inc
NeoNeuro SAS
NeoProgen Inc
NervGen Pharma Corp
NeuExcell Therapeutics Inc
Neuracle Science Co Ltd
Oleolive LLC
Oligomerix inc
OncoSynergy Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
Orpheris Inc
Orphi Therapeutics Inc
Oryzon Genomics SA
OTR3 SAS
Overseas Pharmaceuticals Ltd
Oxstem Ltd
P2D Inc
Palisade Bio, Inc
Panorama Researchama Research
Paramag Biosciences
Transposon Therapeutics Inc
Treeway BV
Treventis Corp
Tria Bioscience Corp
Triplet Therapeutics Inc
TrueBinding Inc
UCB SA
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
USA Elixiria Biotech Inc
Vaccinex Inc
Vanworld Pharmaceutical (Rugao) Company Ltd
Varinel Inc
Vaxxinity Inc
VectorY Therapeutics Inc
VFP Therapies
Videns Incorp Ltd
Virogenics Inc
Vitruvian Biomedical Inc
Vivoryon Therapeutics NV
Vivreon Biosciences LLC
Voronoi Group
Voyager Therapeutics Inc
Vybion Inc
Whan In Pharm Co Ltd
Wren Therapeutics Ltd
Xcelthera INC
Xenexus Pharmaceuticals Pty Ltd
Xigen SA
Xonovo Inc
Yasham P2D Lifesciences Pvt Ltd
Yuhan Corp
Yuma Therapeutics Corp
Yumanity Therapeutics Inc
Zensun (Shanghai) Sci & Tech Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Zhittya Genesis Medicine Inc
ZZ Biotech LLC
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.